Shuangshuang Jia

Shuangshuang Jia

Auto-generated profile, based on publicly available information

Shuangshuang Jia

Institute of Blood Transfusion and Hematology, Guangzhou Blood Center Guangzhou Medical University Guangzhou China

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
13 January 2023 in Blood
Verified
Journal Article
Open access
PDF file
YJYanli Ji
Yanli Ji
YLYalin Luo
Yalin Luo
JWJizhi Wen
Jizhi Wen
YSYuanfan Sun
Yuanfan Sun
SJShuangshuang Jia
Shuangshuang Jia
YFYongshui Fu
Yongshui Fu
Red blood cells (RBCs) of the Asian-type DEL phenotype express few RhD proteins and are typed as serologic RhD-negative (D-) in routine testing. RhD-positive (D+) RBC transfusion for Asian-type DEL patients has been proposed but has not been generally adopted due to a lack of direct evidence regarding its safety and underlying mechanism. We performed a single-arm multicenter clinical trial to document the outcome of D+ RBC transfusion in Asian-type DEL patients; none of the recipients (0/42; 95% confidence interval, 0%-8.40%) developed alloanti-D after a median follow-up of 226 days. We conducted a large retrospective study to detect alloanti-D immunization in 4,045 serologic D- pregnant women throughout China; alloanti-D was found only in true D- individuals (2.63%, 79/3,009), but not in those with Asian-type DEL (0/1,032). We further retrospectively examined 127 serologic D- pregnant women who had developed alloanti-D and found none with Asian-type DEL (0/127). Finally, we analyzed RHD transcripts from Asian-type DEL erythroblasts and examined antigen epitopes expressed by various RHD transcripts in vitro, finding a low abundance of full-length RHD transcripts (0.18% of the total) expressing RhD antigens carrying the entire repertoire of epitopes, which could explain the immune tolerance against D+ RBCs. Our results provide multiple lines of evidence that individuals with Asian-type DEL cannot produce alloanti-D when exposed to D+ RBCs following transfusion or pregnancy. Therefore, we recommend considering D+ RBC transfusion and discontinuing anti-D prophylaxis in Asian-type DEL patients, including pregnant women. This clinical trial is registered at www.clinicaltrials.gov as NCT03727230.

23 March 2025 in Transfusion
Verified
Journal Article
Closed access
RZRan Zhang
Ran Zhang
JWJizhi Wen
Jizhi Wen
CTChangjiu Tang
Changjiu Tang
SJShuangshuang Jia
Shuangshuang Jia
QCQi Chen
Qi Chen
YJYanli Ji
Yanli Ji

4 August 2022 in Transfusion
Verified
Journal Article
Closed access
SJShuangshuang Jia
Shuangshuang Jia
SLSi Li
Si Li
ZLZhijian Liao
Zhijian Liao
CMChunyan Mo
Chunyan Mo
QFQun Fang
Qun Fang
YJYanli Ji
Yanli Ji


20 June 2025 in Transfusion
Verified
Journal Article
Closed access
SJShuangshuang Jia
Shuangshuang Jia
MSMingming Sun
Mingming Sun
CBCaroline Bénech
Caroline Bénech
GRGaëlle Richard
Gaëlle Richard
YJYanli Ji
Yanli Ji
YFYann Fichou
Yann Fichou

19 March 2024 in Transfusion
Verified
Journal Article
Closed access
CMChunyan Mo
Chunyan Mo
SJShuangshuang Jia
Shuangshuang Jia
GLGuangping Luo
Guangping Luo
YJYanli Ji
Yanli Ji